Log in
  • Home
  • Journal & Publications
  • Literature Updates
  • Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Trial

Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Trial

February 25, 2019 16:42 | CINP Office (Administrator)

Long-term remission is an important treatment goal in schizophrenia. Cariprazine, a dopamine D₃/D₂ receptor and serotonin 5-HT1A receptor partial agonist, is approved in the United States and Europe to treat adults with schizophrenia.

Correll C.U., Potkin S.G., Zhong Y., Harsányi J., Szatmári B., Earley W.

Click here for full article.

©2019 CINP | CINP is a registered Scottish Charity, no: SC042462